Program
olomorasib
Also written as “Olomorasib”, “LY3537982” and “[¹⁴C]-LY3537982”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Colorectal Neoplasms · Renal Insufficiency · Hepatic Insufficiency, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Eli Lilly | 145 open or running | phase 3since Nov 1, 2023 | Jul 2, 2021 | Apr 2027phase 2 · NCT04956640 |
| Daiichi Sankyo | 11 open or running | phase 2since Oct 16, 2026 | Oct 16, 2026 | Sep 30, 2029phase 2 · NCT07890714 |
| Johnson & Johnson | 11 open or running | phase 2since Nov 10, 2025 | Nov 10, 2025 | Nov 30, 2028phase 2 · NCT07227025 |
- Named in Eli Lilly’s own pipeline as
Olomorasib
, phase 3, as of Oct 29, 2026 (source).
Also a collaborator on its studies: AstraZeneca and Merck.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 1 study since Jul 2, 2021.
- Apr 11, 2023Phase 1 study in HealthyEli Lilly · NCT05824858 · 48 enrolled · United States
- Jun 4, 2023Phase 1 study in HealthyEli Lilly · NCT05901311 · 16 enrolled · United States
- Oct 27, 2023Phase 1 study in HealthyEli Lilly · NCT06111521 · 35 enrolled · United States
- Nov 1, 2023Phase 3 study in Carcinoma, Non-Small-Cell LungEli Lilly · NCT06119581 · 1,264 planned · United States, Australia, Austria and more
- Jan 24, 2024Phase 1 study in Advanced Solid TumorsEli Lilly · NCT06235983 · 12 enrolled · China
- Dec 2, 2024Phase 1 study in Hepatic InsufficiencyEli Lilly · NCT06719128 · 46 enrolled · United States
- Mar 18, 2025Phase 3 study in Carcinoma, Non-Small-Cell LungEli Lilly · NCT06890598 · 700 planned · United States, Australia, Austria and more
- Jun 26, 2025Phase 1 study in HealthyEli Lilly · NCT07044271 · 120 enrolled · United States
- Aug 13, 20252 phase 1 studiesEli Lilly · NCT07124013, NCT07137689
- Nov 10, 2025Johnson & Johnson's first study: phase 2 study in Carcinoma, Non-Small-Cell LungNew to Johnson & JohnsonJohnson & Johnson · NCT07227025 · 60 planned · United States, Canada, China and more
- Feb 24, 2026Phase 1 study in HealthyEli Lilly · NCT07439250 · 15 enrolled · United States
- Aug 26, 2026Phase 1 study in Healthy VolunteersEli Lilly · NCT07794592 · 24 planned · United States
- Sep 4, 2026Phase 2 study in Colorectal NeoplasmsEli Lilly · NCT07814417 · 50 planned · United States, China, Spain
- Oct 16, 2026Daiichi Sankyo's first study: phase 2 study in Carcinoma, Non-Small-Cell LungNew to Daiichi SankyoDaiichi Sankyo · NCT07890714 · 268 planned · Taiwan
Ahead
- Apr 2027Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungEli Lilly · NCT04956640
- Nov 2027Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungEli Lilly · NCT06119581
- Nov 2028Primary completion: phase 2 study in Colorectal NeoplasmsEli Lilly · NCT07814417
- Nov 30, 2028Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungJohnson & Johnson · NCT07227025
TargetBeta
“An orally available inhibitor of the oncogenic KRAS substitution mutation, G12C, with potential antineoplastic activity. Upon oral administration, olomorasib selectively targets the KRAS G12C mutant and inhibits KRAS G12C mutant-dependent signaling. KRAS, a member of the RAS family of oncogenes, …”NCIt, read by Claude
“An orally available inhibitor of the oncogenic KRAS substitution mutation, G12C, ”NCIt, by rule
Other programs on KRAS
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| sotorasibrule | Amgen | phase 3 | 28 |
| adagrasibrule | Bristol-Myers Squibb | phase 3 | 16 |
| divarasib | Hoffmann-La Roche | phase 3 | 13 |
| KRAS G12D Inhibitor VS-7375rule | Genfleet Therapeutics (Shanghai) | phase 3 | 12 |
| glecirasibrule | Allist Pharmaceuticals | phase 3 | 12 |
| calderasib | Merck | phase 3 | 12 |
| daraxonrasibrule | Revolution Medicines | phase 3 | 10 |
| garsorasibrule | InventisBio | phase 3 | 8 |
| KRAS G12D Inhibitor HRS-4642 | Jiangsu HengRui Medicine | phase 3 | 7 |
| zoldonrasibrule | Revolution Medicines | phase 3 | 6 |
| HRS-7058 | Jiangsu HengRui Medicine | phase 3 | 6 |
| opnurasibrule | Novartis | phase 3 | 5 |
Studies
All 16 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07890714Carcinoma, Non-Small-Cell Lung · Taiwan | 2 | Recruiting | Daiichi Sankyo | Sep 30, 2029 | 268 |
| NCT07814417Colorectal Neoplasms · United States, China, Spain | 2 | Not yet recruiting | Eli Lilly | Nov 2028 | 50 |
| NCT07794592Healthy Volunteers · United States | 1 | Recruiting | Eli Lilly | Oct 2026 | 24 |
| NCT07439250Healthy · United States | 1 | Completed | Eli Lilly | Apr 17, 2026 | 15 |
| NCT07227025Carcinoma, Non-Small-Cell Lung · United States, Canada, China and more | 2 | Recruiting | Johnson & Johnson | Nov 30, 2028 | 60 |
| NCT07137689Renal Insufficiency · United States | 1 | Completed | Eli Lilly | Apr 10, 2026 | 32 |
| NCT07124013Healthy · Japan | 1 | Completed | Eli Lilly | Jan 5, 2026 | 191 |
| NCT07044271Healthy · United States | 1 | Completed | Eli Lilly | Nov 8, 2025 | 120 |
| NCT06890598Carcinoma, Non-Small-Cell Lung · United States, Australia, Austria and more | 3 | Recruiting | Eli Lilly | May 2029 | 700 |
| NCT06719128Hepatic Insufficiency · United States | 1 | Completed | Eli Lilly | Aug 25, 2025 | 46 |
| NCT06235983Advanced Solid Tumors · China | 1 | Completed | Eli Lilly | Jul 2, 2025 | 12 |
| NCT06119581Carcinoma, Non-Small-Cell Lung · United States, Australia, Austria and more | 3 | Recruiting | Eli Lilly | Nov 2027 | 1,264 |
| NCT06111521Healthy · United States | 1 | Completed | Eli Lilly | Apr 1, 2024 | 35 |
| NCT05901311Healthy · United States | 1 | Completed | Eli Lilly | Aug 10, 2023 | 16 |
| NCT05824858Healthy · United States | 1 | Completed | Eli Lilly | Jun 17, 2023 | 48 |
| NCT04956640Carcinoma, Non-Small-Cell Lung · United States, Australia, Canada and more | 2 | Active, not recruiting | Eli Lilly | Apr 2027 | 540 |
How it is read
Names in the registry
- “Olomorasib”, 8 entries
- “LY3537982”, 7 entries
- “[¹⁴C]-LY3537982”, 2 entries
- “Olomorasib test”, 1 entry
- “Olomorasib reference”, 1 entry
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 5 studies
- Colorectal Neoplasms, 1 study
- Renal Insufficiency, 1 study
- Hepatic Insufficiency, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.